PANAXIA LABS ISRAEL LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,578 ILa | +24.76% |
|
+14.79% | -36.10% |
| 31/03 | Panaxia Labs Israel Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 10/01 | Joseph Herman acquired 3.33% stake in Panaxia Labs Israel Ltd for ILS 1 million. | CI |
| Sales 2022 | 39.42M 10.35M 3.94B 863M | Sales 2023 | 19.59M 5.15M 1.96B 429M | Capitalization | 22.44M 5.89M 2.24B 492M |
|---|---|---|---|---|---|
| Net income 2022 | -43M -11.29M -4.3B -942M | Net income 2023 | -13M -3.41M -1.3B -285M | EV / Sales 2022 | 1.63 x |
| Net Debt 2022 | 36.12M 9.49M 3.61B 791M | Net Debt 2023 | 36.1M 9.48M 3.61B 791M | EV / Sales 2023 | 2.99 x |
| P/E ratio 2022 |
-0.65
x | P/E ratio 2023 |
-168
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 37.69% |
More Fundamentals
* Assessed data
More news
| 1 day | +24.76% | ||
| 1 week | +14.79% | ||
| Current month | -19.72% | ||
| 1 month | -13.79% | ||
| 3 months | -18.28% | ||
| 6 months | +21.09% | ||
| Current year | -36.10% |
1 week
7 550.00
10 300.00
1 month
7 550.0014 500.00
Current year
7 550.0015 600.00
1 year
2 020.0017 170.00
3 years
2 020.00219 400.00
5 years
2 020.00456 000.00
10 years
2 020.00456 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Dadi Segal
CEO | Chief Executive Officer | 48 | 01/19/01 |
Assi Rotbart
CHM | Chairman | 49 | 01/19/01 |
| Director of Finance/CFO | 66 | 28/22/28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michal Yageel
BRD | Director/Board Member | 53 | 29/21/29 |
Tal Yaron Eldar
BRD | Director/Board Member | 60 | 21/16/21 |
Michal Sapir
BRD | Director/Board Member | 66 | 17/22/17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/24/25 | 9,578 | +24.76% | 1,098 |
| 24/24/24 | 7,677 | -5.41% | 168 |
| 21/24/21 | 8,116 | -2.73% | 270 |
Delayed Quote TEL AVIV STOCK EXCHANGE, April 25, 2024 at 04:54 pm IST
More quotes
Panaxia Labs Israel Ltd is an Israel-based company that is principally engaged in cannabis industry. The Company provides pharma-grade smokeless cannabis products that provide better delivery systems for patients and physicians when properly assessing safety and dosage. Panaxia pharmaceutical cannabis products are specifically tailored to meet a broad range of needs. It's product portfolio includes: NAXIVA-PANAXOL Advanced kit for preparation of cannabis oil-standardized extract, NAXIVA-PANAXOL Purified extract for inhalation, PANAXIR Medical Cannabis Orodispersible Tablets, PANAXIR SENSE Orange Creamsicle Medical cannabis sublingual drops, PANAXIR CBD Melatonin Tablets, PANAXIR Medical cannabis extracts in ethanol among others.
Sector
Business Support Services
| 1st Jan change | Capi. | |
|---|---|---|
| -36.10% | 3.76M | |
| +10.55% | 67.6B | |
| +11.64% | 18.21B | |
| +21.03% | 13.41B | |
| +9.40% | 13.37B | |
| +16.53% | 9.94B | |
| -32.90% | 5.74B | |
| -10.98% | 5.57B | |
| -4.09% | 4.91B | |
| -4.83% | 4.87B |
- Stock Market
- Equities
- PNAX Stock
